<DOC>
	<DOCNO>NCT02879513</DOCNO>
	<brief_summary>This trial compare administration 2 cycle paclitaxel cisplatin ( DP ) versus 4 cycle CEF adjuvant chemotherapy patient locally advance breast cancer pathological partial response DP neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Trial Adjuvant Chemotherapy Breast Cancer Patients With Pathological Partial Response Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>All patient neoadjuvant chemotherapy pathological complete response ( pCR ) partial response DP enrol trial . Those pCR continue two cycle DP adjuvant chemotherapy . This arm consider control arm . Those patient PR randomize two cycle DP four cycle CEF . All patient hormonal receptor positive Her2 overexpress tumor allow accept endocrine therapy anti-Her2 target therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Women age ≥18years ≤70 year ; 2 . Patients locally advance breast caner weekly paclitaxel cisplatin neoadjuvant chemotherapy . 3 . Patients pathological partial response pathological complete response neoadjuvant chemotherapy accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 4 . Endocrine therapy trastuzumab allow use . 5 . ECOG 02 ; 6 . Adequate bone marrow function : WBC≥4.0×109/L , Absolute neutrophil count（ANC）≥1.5×109/L , Platelets（PLT）≥100×109/L , Hemoglobin（Hb）≥90g/L ; aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) ≤1.5 upper normal limit ( UNL ) , creatinine≤1.5 UNL , bilirubin≤1.5UNL ; 7 . No obvious main organ dysfunction . 1 . Unwilling unable use acceptable method contraception 8 week ( include 8 week ) final dose test drug ; 2 . Patient pregnant breast feeding ; 3 . Metastatic breast cancer ; 4 . Any evidence sense motor nerve disorder ; 5 . Patients medical condition taht indicate intolerant neoadjuvant therapy , include uncontrolled cardiovascular disease , severe infection ; 6 . Any concurrent malignancy breast cancer ; 7 . Know severe hypersensitivity drug study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>